The firm priced its offering at $2.40 per share and expects to raise $8.4 million in gross proceeds. It plans to use the funds for product development, clinical studies, and product development.
The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.
The firm plans to use the $13.3 million in net proceeds to fund ongoing operations, expansions of its liquid biopsy business, and to service its indebtedness.
The company plans to use proceeds to support its ongoing operations, expansion of its business, and to service existing debts.
The company said it anticipates using net proceeds for working capital and general corporate purposes.
The firm is offering 12.1 million shares of its common stock at a price to the public of $2.90 per share, for expected gross proceeds of $35.1 million.
Net proceeds from the offering of more than 4.9 million shares will be used for working capital and other general corporate purposes.
The offering was a follow-on to a capital raise during the summer that brought in $6 million. The company's CEO said the additional financing was needed to execute on its business plan.
The firm raised €4.7 million through a conditional placement, and €5.0 million through an unconditional direct subscription.
The firm, which said last week it expected to raise $15.9 million, has said it will use the net proceeds for working capital and general corporate purposes.